Learn More.
The latest news and answers to frequently asked questions about the CNSide® CSF Assay Platform and its applications
Press Releases
October 21, 2025
September 25, 2025
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
September 18, 2025
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
July 10, 2025
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
Presentations
August 15, 2025 // SNO ASCO CNS Metastases Conference
LM KOL Symposium: “Reimaging Your Approach to Leptomeningeal Metastases”
August 15, 2025 // SNO ASCO CNS Metastases Conference
CSFTumorCell (CSF-TC)Detection, Quantification and Biomarker Assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease (FORESEE Study,NCT05414123) – Blue Ribbon Recipient Poster
August 15, 2025 // SNO ASCO CNS Metastases Conference
The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CST-TCs) Reveals Implications for Differential Treatment of the LMD Tumor
November 24, 2024 // SNO Annual Meeting
CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease (FORESEE Study, NCT-5414123)
November 22, 2024 // SNO Annual Meeting
The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the LMD Tumor
August 10, 2024 // SNO ASCO CNS Metastases Conference
CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment helps in clinical management of breast cancer and Non-Small Cell Lung cancer patients having Leptomeningeal Disease (FORESEE Study, NCT05414123)
August 8, 2024 // SNO ASCO CNS Metastases Conference
Update on CSF Diagnostics in LMD: Because all that enhances ISN’T cancer
Frequently Asked Questions
Find answers to common questions about the CNSide® CSF Assay Platform and its applications.
PATIENT FAQs
What is the CNSide® CSF Assay Platform?
A set of diagnostic tests that identify and analyze tumor cells and circulating tumor DNA in cerebrospinal fluid, aiding in the management of leptomeningeal metastases.
How does the CNSide® CSF Assay Platform work?
The CNSide® CSF Assay Platform uses advanced molecular techniques to detect and quantify tumor cells and DNA in cerebrospinal fluid samples, providing detailed insights for clinical decision-making.
Who can benefit from the CNSide® CSF Assay Platform?
Patients with leptomeningeal metastases from carcinomas or melanomas can benefit from the precise and comprehensive analysis provided by the CNSide® CSF Assay Platform.
Does the CNSide® CSF Assay Platform require a procedure?
Yes, the CNSide® CSF Assay Platform requires an outpatient procedure to collect a patient’s cerebrospinal fluid via lumbar puncture or Ommaya reservoir.
How does the CNSide® CSF Assay Platform improve patient outcomes?
By providing accurate and detailed molecular data, the CNSide® CSF Assay Platform helps healthcare providers make informed treatment decisions, leading to better patient outcomes.
Where and when can healthcare providers get the CNSide® CSF Assay Platform?
The CNSide® CSF Tumor Cell Enumeration test is now available in the state of Texas through CNSide® Diagnostics, LLC, a subsidiary of Plus Therapeutics, Inc. The CNSide® CSF ICC, FISH, and NGS tests are estimated to be available in the U.S. starting in 2026. Contact us for more information on how to access this novel CSF Assay Platform.
How can patients with Leptomeningeal Metastases have their CSF evaluated by CNSide®?
Patients should contact their healthcare provider: neuro-oncologist, medical oncologist, or neuroimmunologist.
Is the CNSide® CSF Assay Platform covered by my health insurance?
We are committed to providing the CNSide® CSF Assay Platform to all eligible patients and securing commercial and government (Medicare, Medicaid) insurance coverage. Today, the CNSide® CSF Tumor Cell Enumeration test is covered by UnitedHealthcare and Humana.
Discover More About CNSide®
Disease Overview
Challenges of Diagnosis
Treatment Options
Patient Advocacy and Resources
Contact Form
Partnerships
Join the Interest List
support@CNSide-Dx.com
Phone: 877-288-4174
Fax: 858-875-5209
© 2025 CNSide Diagnostics, LLC is a subsidiary of Plus Therapeutics, Inc. CNSide is a trademark of CNSide Diagnostics, LLC. All rights reserved.
The CNSide® Cerebrospinal Fluid Assay Platform consists of four Laboratory Developed Tests (LDTs) for research use only, manufactured by and used within the CNSide Diagnostics, LLC’s lab in Houston, Texas with a single CLIA certificate. Analytical validation is limited to the specific conditions, staff, equipment and patient population of the laboratory, and the findings of these laboratory-specific analytical validation are meaningful within the laboratory setting. This assay cannot be used for clinical diagnostic procedures or any purpose other than research or investigation and the collection kit is prominently labeled ‘for Research Use Only (RUO)’ prior to shipment or delivery to the laboratory. The clinical performance characteristics of this product are not established.
Privacy Policy
Terms of Use
Forward Looking Statement
Social Media Guidelines